Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	[1]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (116,746)	$ (75,229)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expenses	738	742
Changes in operating assets and liabilities:
Decrease in accrued liabilities	(21,067)	(9,000)
Increase in prepaid expenses	(1,057)	(4,850)
Net cash flows used in operating activities	(138,132)	(88,337)
CASH FLOWS USED IN INVESTING ACTIVITIES:
Additional of accumulation cost of biological assets	(6,866)	(7,173)
Net cash flows used in investing activities	(6,866)	(7,173)
CASH FLOWS FROM FINANCING ACTIVITIES
Advance from directors	12,148	27,157
Net cash provided by financing activities	12,148	27,157
Effect of exchange rate changes in cash and cash equivalents	(60)	(490)
Net changes in cash and cash equivalents	(132,910)	(68,843)
Cash and cash equivalents, beginning of period	261,930	448,684
CASH AND CASH EQUIVALENTS, END OF YEAR/PERIOD	129,020	379,841
SUPPLEMENTAL CASH FLOWS INFORMATION
Income taxes paid
Interest paid

[1] The prior year comparative information has been retrospectively stated due to the common control acquisition on September 30, 2018.